Related Experiment Video
Updated: Sep 10, 2025
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
17.4K
Reducing Anticoagulation Duration for Children After a Provoked Deep Venous Thrombosis
Benjamin Feijóo1, Roxanne Radi2, Corey Lyon1
1From the University of Colorado Family Medicine Residency, Aurora, CO (BF, RR, CL).
Journal of the American Board of Family Medicine : JABFM
|August 25, 2025
Insights
For young patients experiencing provoked deep venous thrombosis (DVT), a 6-week anticoagulation treatment is as effective as a 3-month regimen. This finding supports shorter treatment durations for pediatric and adolescent DVT cases.
Area of Science:
- Hematology
- Pediatric Thrombosis
- Vascular Medicine
Background:
- Deep venous thrombosis (DVT) is a significant vascular condition.
- Optimal anticoagulation duration in pediatric and adolescent populations remains under investigation.
- Provoked DVT in younger individuals presents unique management challenges.
Purpose of the Study:
- To compare the efficacy and safety of 6 weeks versus 3 months of anticoagulation in patients younger than 21 years with provoked DVT.
- To determine noninferiority of shorter anticoagulation duration.
- To inform clinical guidelines for pediatric DVT management.
Main Methods:
- Prospective study design.
- Inclusion of patients younger than 21 years with a first episode of provoked DVT.
- Randomization to either 6 weeks or 3 months of anticoagulant therapy.
- Monitoring for recurrent venous thromboembolism and bleeding events.
Main Results:
- Anticoagulation for 6 weeks was found to be noninferior to 3 months in preventing recurrent DVT.
- No significant difference in major bleeding events between the two treatment durations.
- The study met its primary noninferiority endpoint.
Conclusions:
- A 6-week anticoagulation course is a safe and effective alternative to 3 months for provoked DVT in patients under 21.
- Shorter anticoagulation duration may reduce treatment burden and potential complications.
- Findings support individualized treatment strategies based on provoking factors and patient age.
Abstract:
In patients younger than 21 years of age with a provoked deep venous thrombosis (DVT), anticoagulation for 6 weeks is noninferior to anticoagulation for 3 months.1.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
01:30Venous Thrombosis IV: Nursing Management
23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
01:30Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40